Melanoma Clinical Trial
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Summary
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients. This data analysis for this study will also include data from 9 Amgen-sponsored clinical studies in adult participants with stage IIIB-IVM1c melanoma.
Eligibility Criteria
Inclusion Criteria:
Patient has provided written informed consent
Patient is an adult (≥ 18 years of age at the time of informed consent) with a diagnosis of melanoma
Patient enrolled within 1 month of receiving the first dose of IMLYGIC for the treatment of melanoma
Exclusion Criteria:
- Patient has a prior history of being a subject in an interventional clinical trial for IMLYGIC
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Jefferson City Missouri, 65109, United States
Cincinnati Ohio, 45242, United States
Pittsburgh Pennsylvania, 15213, United States
Knoxville Tennessee, 37920, United States
Murray Utah, 84107, United States
Madison Wisconsin, 53792, United States
Graz , 8036, Austria
Linz , 4020, Austria
Salzburg , 5020, Austria
Sankt Poelten , 3100, Austria
Haifa , 31096, Israel
Ramat Gan , 52620, Israel
Basel , 4052, Switzerland
Chur , 7000, Switzerland
Zuerich Flughafen , 8058, Switzerland
Cheltenham , GL53 , United Kingdom
Oxford , OX3 7, United Kingdom
How clear is this clinincal trial information?